1,3-diazabicyclo[5.4.0]-undec-7-ene | 196392-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 1,3-diazabicyclo[5.4.0]-undec-7-ene
• 英文别名: DBU；1,3-Diazabicyclo (5,4,0)undec-7-ene；1,2,3,4,5,7,8,9-octahydropyrido[1,2-c][1,3]diazepine
• CAS: 196392-14-0
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: QTEYOHOQLZFKFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-(difluoromethoxy)-8-nitrodibenzo[b,d]furan-1-yl)-4,5-dihydrooxazole-4-carboxylate 、 1,3-diazabicyclo[5.4.0]-undec-7-ene 、 水 在 二氯甲烷 、 Sodium sulfate-III 作用下， 以 乙腈 、 四氯化碳 、 吡啶 为溶剂， 反应 1.0h， 生成 ethyl 2-(4-(difluoromethoxy)-8-nitrodibenzo[b,d]furan-1-yl)-1,3-oxazole-4-carboxylate
  参考文献：
  名称：

  Heterocyclic compounds as phosphodiesterase inhibitors

  摘要：

  化合物的公式(I)、它们的衍生物、类似物、互变异构体、区域异构体、立体异构体、多晶形、溶剂物、中间体、药学上可接受的盐、药物组合物、N-氧化物、代谢物和其前药。这些化合物是磷酸二酯酶4型（PDE4）抑制剂。它们对治疗各种过敏或炎症性疾病有用，包括哮喘、慢性阻塞性肺病、慢性支气管炎、特应性皮炎、过敏性鼻炎、过敏性结膜炎、春季结膜炎、牛皮癣、类风湿性关节炎、溃疡性结肠炎、克罗恩病、葡萄膜炎和狼疮。

  公开号：

  US08580795B2

文献信息

• 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20160030384A1

  公开（公告）日：2016-02-04

  The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

  这项发明提供了萘呋喃化合物，萘呋喃化合物的多晶形态，颗粒形式的萘呋喃化合物，含有一种或多种萘呋喃化合物的纯化组合物，含有一种或多种颗粒形式的萘呋喃化合物的纯化组合物，以及
• CATIONIC LIPID
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20140294978A1

  公开（公告）日：2014-10-02

  The present invention provides a cationic lipid and the like. The cationic lipid is for delivering a medicament containing a cationic lipid which facilitates the introduction of a nucleic acid into a cell or the like, and is represented by formula (I). In the formula, R 1 is linear or branched alkyl, alkenyl, or alkynyl, each having 8 to 24 carbon atoms, R 2 is linear or branched alkyl, alkenyl, or alkynyl, each having 8 to 24 carbon atoms, or alkoxyethylene, alkoxypropylene, alkenyloxyethylene, alkenyloxypropylene, alkynyloxyethylene, or alkynyloxypropylene, R 3 and R 4 may be the same or different, and are each alkyl having 1 to 3 carbon atoms or are combined together to form alkylene having 2 to 6 carbon atoms, or R 3 and R 5 are combined together to form alkylene having 2 to 6 carbon atoms, R 5 is a hydrogen atom, alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, or the like, or is combined together with R 3 to form alkylene having 2 to 6 carbon atoms, X is alkylene having 1 to 6 carbon atoms, and Y is a single bond, alkylene having 1 to 6 carbon atoms, or the like.

  本发明提供了一种阳离子脂质等。该阳离子脂质用于传递含有阳离子脂质的药物，有助于将核酸引入细胞或类似物中，并由式(I)表示。在该式中，R1为具有8到24个碳原子的线性或支链烷基、烯基或炔基，R2为具有8到24个碳原子的线性或支链烷基、烯基或炔基，或者为烷氧乙烯、烷氧丙烯、烯氧乙烯、烯氧丙烯、炔氧乙烯或炔氧丙烯，R3和R4可以相同也可以不同，分别为具有1到3个碳原子的烷基，或者结合在一起形成具有2到6个碳原子的烷基，或者R3和R5结合在一起形成具有2到6个碳原子的烷基，R5为氢原子、具有1到6个碳原子的烷基、具有3到6个碳原子的烯基、氨基、单烷基氨基、羟基、烷氧基、氨基甲酰基、单烷基氨基甲酰基、二烷基氨基甲酰基等，或者与R3结合在一起形成具有2到6个碳原子的烷基，X为具有1到6个碳原子的烷基，Y为单键、具有1到6个碳原子的烷基等。
• Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
  申请人：——

  公开号：US20030229136A1

  公开（公告）日：2003-12-11

  Novel compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) 1 wherein R 1 through R 3 and R 5 through R 11 are defined herein, and &agr;, &bgr; and &ggr; are optional bonds, providing that when &agr; is absent, &bgr; is present, and when &bgr; is absent, &agr; is present. When &agr; is present, preferred R 4 moieties are selected from O, S, NH and CH 2 , and when &agr; is absent, preferred R 4 groups are selected from OH, SH, NH 2 and CH 3 . When &ggr; is present, the preferred R 5 substituent is O, while when &ggr; is absent, the preferred R 5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

  提供了作为化疗、化学预防和抗血管生成的有用化合物。这些化合物是类黄酮类化合物，包括黄酮酮、黄烷醇和香豆素。这些化合物具有公式（I）的结构，其中R1至R3和R5至R11在此定义，α、β和γ为可选键，当α不存在时，β存在，当β不存在时，α存在。当α存在时，首选的R4基团从O、S、NH和CH2中选择，当α不存在时，首选的R4基团从OH、SH、NH2和CH3中选择。当γ存在时，首选的R5取代基是O，而当γ不存在时，首选的R5取代基是OH。还提供了药物组合物，以及合成和使用方法。
• [EN] NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS POUR LE CIBLAGE DE CELLULES SOUCHES CANCÉREUSES
  申请人：BOSTON BIOMEDICAL INC

  公开号：WO2011116398A1

  公开（公告）日：2011-09-22

  The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

  本发明提供萘呋酮化合物，萘呋酮化合物的多晶形态，颗粒形式的萘呋酮化合物，含有一种或多种萘呋酮化合物的纯化组合物，含有一种或多种颗粒形式的萘呋酮化合物的纯化组合物，制备这些萘呋酮化合物、多晶形态、纯化组合物和/或颗粒形式的方法，以及使用这些萘呋酮化合物、多晶形态、纯化组合物和/或颗粒形式的方法来治疗需要的受试者的方法。
• HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
  申请人：Balasubramanian Gopalan

  公开号：US20110269753A1

  公开（公告）日：2011-11-03

  Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.

  化合物的公式（I），它们的衍生物，类似物，互变异构体，区域异构体，立体异构体，多晶形，溶剂化物，中间体，药学上可接受的盐，药物组合物，N-氧化物，代谢物和其前药。这些化合物是磷酸二酯酶4型（PDE4）抑制剂。它们在治疗各种过敏性或炎症性疾病方面很有用，包括哮喘，COPD，慢性支气管炎，特应性皮炎，过敏性鼻炎，过敏性结膜炎，春季性结膜炎，牛皮癣，类风湿性关节炎，溃疡性结肠炎，克罗恩病，葡萄膜炎和红斑狼疮。